DTR Price sensitive 9 Dec 2025, 2:54 PM

Response to Media Speculation

Dateline Resources Ltd

Dateline Resources Denies Legal Claims Over REE Tenements

Key points

  • Dateline CEO investigating additional REE tenements
  • Denies any contractual arrangements with USC/Gladiator
  • Will vigorously defend any legal proceedings by USC/Gladiator

Full summary

Dateline Resources Limited (ASX: DTR) has responded to recent media reports following an ASX announcement by US 1 Critical Minerals Limited (ASX: USC), previously known as Gladiator Resources Limited (USC/Gladiator). USC/Gladiator had commenced legal proceedings against Dateline's CEO, Mr Stephen Baghdadi, in an attempt to obtain transfer of certain potentially promising Rare Earth Elements (REE) tenements in the USA. In response, Dateline's Board can confirm that following the successful identification of the Colosseum Gold - REE Project, its CEO continues to investigate and take steps to secure additional potentially promising REE tenements. However, Dateline emphatically denies that it, Stephen Baghdadi, or any associated entities have any contractual arrangements with USC/Gladiator in relation to such tenements. Dateline states that if it does secure additional REE tenements, it will seek to commercialise them for the benefit of all Dateline shareholders and will not agree to transfer them to another party in return for a reimbursement of its costs, as alleged by USC/Gladiator. The Board confirms that any legal proceedings against the Company and/or its CEO by USC/Gladiator will be vigorously defended.Dateline's Chairman, Mr Mark Johnson, praised the efforts of the Managing Director, Mr Stephen Baghdadi, in identifying and negotiating the Colosseum opportunity, as well as his management of government and regulatory engagements. The Chairman stated that any additional REE tenements identified and cultivated by Mr Baghdadi will accrue for the benefit of Dateline and its shareholders on terms approved by the Board.

Summary generated by a large language model. Please interpret with care.

Sign in for more about this company, including guidance changes and other insights.
Sign in